Plasticity of visual evoked potentials in patients with neurofibromatosis type 1

• Published in: Clinical neurophysiology 2022-10, Vol.142, p.220-227
• Main Authors: Castricum, J., Tulen, J.H.M., Heuvelmans, A.M., Geleijnse, G., Straver, D.C.G., Taal, W., Kushner, S.A., Elgersma, Y.
• Format: Article
• Language: English
• Subjects: cortical plasticity; neurofibromatosis type 1; visual evoked potentials
• ISSN: 1388-2457; 1872-8952
• DOI: 10.1016/j.clinph.2022.08.009

•Studying VEP plasticity might be a novel neurophysiological outcome measure associated with cognitive disability in NF1.•The NF1 group had a non-potentiated response to VEP induction.•The control group revealed a potentiated VEP response during continuous visual stimulation without delay. The inability to properly process visual information has been frequently associated with neurofibromatosis type 1 (NF1). Based on animal studies, the cause of cognitive disabilities in NF1 is hypothesized to arise from decreased synaptic plasticity. Visual cortical plasticity in humans can be investigated by studying visual evoked potentials (VEPs) in response to visual stimulation. VEP plasticity was assessed by measuring the increase of the peak amplitudes C1, P1, and N1 induced by 10-min modulation of checkerboard reversals in 22 adult NF1 patients and 30 controls. VEP signals were recorded pre-modulation, during modulation, and at 2, 7, 12, 17, 22, 27 min post-modulation. The P1 amplitude increased significantly comparing post-modulation to pre-modulation in the control group. This potentiation was not observed in the NF1 group. Visual cortical plasticity could be measured using VEPs in response to visual stimulation in the control group. Individuals with NF1 may have reduced visual cortical plasticity, as indicated by their non-potentiated response to VEP induction. These findings should be interpreted with caution due to high inter-subject variability. The present study contributes to an improved assessment of the feasibility for using neurophysiological outcome measures in intervention studies of cognitive deficits among patients with NF1.